ACSL5 drives pancreatic ductal adenocarcinoma by suppressing mitophagy and enhancing ferroptosis resistance via the JAK1-STAT1-OASL axis
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Jingjing Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 3100…. Hauptthemen laut MEDLINE: Ferroptosis, Carcinoma, Pancreatic Ductal, Coenzyme A Ligases, Mitophagy. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Zhejiang Cancer Hospital, National Key Research and Development Program of China.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited therapeutic options. Here, we identify long-chain acyl-CoA synthetase 5 (ACSL5) as a key oncogenic driver and prognostic biomarker in PDAC. Combined transcriptomic analysis of 51 PDAC samples and three public databases (GSE183795, GSE28735, GSE62452) reveals that ACSL5 is markedly upregulated in PDAC, and its overexpression is significantly associated with shorter patient survival and high diagnostic accuracy (AUC = 0.899), suggesting robust diagnostic potential. Functional assays demonstrate that ACSL5 promotes PDAC cell proliferation, migration, and tumor growth while inhibiting apoptosis. Mechanistically, ACSL5 activates the JAK1-STAT1 signaling pathway, leading to transcriptional upregulation of oligoadenylate synthetase-like protein (OASL). The ACSL5-OASL axis concurrently suppresses PINK1/Parkin-mediated mitophagy and enhances ferroptosis resistance by modulating GPX4, SLC7A11, and ACSL4 expression. Notably, the mitophagy activator CCCP effectively reverses ACSL5-driven tumor progression and restores ferroptosis sensitivity. Our findings establish ACSL5 as a promising diagnostic and therapeutic target and reveal that targeting mitophagy represents a potential strategy for ACSL5-high PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- Department of Hepatopancreatobiliary Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- Department of Information Engineering, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
- Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Förderung
- Zhejiang Cancer Hospital
- National Key Research and Development Program of China
Zitieren
APA
Dong, J., Dai, M., Zhou, Y., Wu, M., Wu, W., Zhou, L., Ji, Z., Ye, T., Qin, J., Luo, J., Yu, C., & Xu, M. (2026). ACSL5 drives pancreatic ductal adenocarcinoma by suppressing mitophagy and enhancing ferroptosis resistance via the JAK1-STAT1-OASL axis. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218809
Vancouver
Dong J, Dai M, Zhou Y, Wu M, Wu W, Zhou L, et al. ACSL5 drives pancreatic ductal adenocarcinoma by suppressing mitophagy and enhancing ferroptosis resistance via the JAK1-STAT1-OASL axis. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218809
BibTeX
@article{Dong2026,
author = {Dong, Jingjing and Dai, Mengting and Zhou, Yiming and Wu, Mengde and Wu, Wei and Zhou, Linling and Ji, Zhaoyang and Ye, Tongtong and Qin, Jiaying and Luo, Jialu and Yu, Chenhuan and Xu, Mingzhi},
title = {ACSL5 drives pancreatic ductal adenocarcinoma by suppressing mitophagy and enhancing ferroptosis resistance via the JAK1-STAT1-OASL axis},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218809}
}
EUVIMED